Agios Pharmaceuticals (AGIO) – Mitapivat and the 2026 haematology roadmap

1. Where Agios really stands now

A year ago, Agios was still mostly a “promise stock”: one approved niche drug for pyruvate kinase deficiency and a lot of hope around sickle cell disease. Today the picture is more complex but also more concrete: mitapivat now has two U.S. approvals, a full rare-disease haematology franchise is forming, and 2026 has a surprisingly busy catalyst map.

On the market side, AGIO trades in the mid-20s per share as of February 6, 2026, after a violent drawdown in November when the sickle cell trial failed to deliver on pain crises, followed by a relief move around the new approval in thalassemia. :contentReference[oaicite:1]{index=1}

The simple version: mitapivat is no longer just an experiment. It is a real revenue franchise in PK deficiency and thalassemia, with a controversial but still alive story in sickle cell disease.

Two brands from the same engine

Mitapivat is a small-molecule activator of red-cell pyruvate kinase (PKR). In practice, it helps red blood cells produce more ATP and survive longer. The same engine now lives under two brands:

• PYRUKYND® – for adults with pyruvate kinase deficiency (PKD).
• AQVESME™ – for adults with alpha- or beta-thalassemia and anaemia, the first oral treatment approved by the FDA for this indication. :contentReference[oaicite:2]{index=2}

Both are rare, chronic conditions where patients and doctors have lived for years with transfusions, chelation and fatigue as the baseline. That is why regulators and the thalassemia community framed AQVESME as a genuine milestone when the FDA cleared it in late December 2025. :contentReference[oaicite:3]{index=3}

2. Aqvesme and Pk deficiency – the “real world” pillar

The first leg of the story is boring in the best possible way: commercial execution.

PYRUKYND has been slowly building a base of treated PKD patients since its original approval, giving Agios recurring revenue in an ultra-rare niche. The numbers are still small in absolute terms but have been growing double-digit year-on-year, according to previous quarterly updates. :contentReference[oaicite:4]{index=4}

The second, much bigger pillar is AQVESME:

• FDA approved it on December 23, 2025 for anaemia in adults with alpha- or beta-thalassemia, both non-transfusion-dependent and transfusion-dependent. :contentReference[oaicite:5]{index=5}
• It is the only medicine with a label covering both forms, and the first oral option for many patients. :contentReference[oaicite:6]{index=6}
• Pricing has been reported around $425k per patient per year, in line with other ultra-rare therapies and with a boxed warning and liver-function monitoring requirement in the label. :contentReference[oaicite:7]{index=7}

For 2026, Agios has been very explicit: the first strategic priority is to make the thalassemia launch work in the U.S. and to push towards approvals and reimbursement in Europe and other high-prevalence regions. :contentReference[oaicite:8]{index=8}

Key official sources:
– Agios IR – 2026 strategic priorities press release
– FDA Aqvesme approval note
– Thalassemia foundation/Aqvesme community update

3. Sickle cell disease – the trial that broke the chart

The biggest scar on AGIO’s chart comes from RISE UP, the Phase 3 trial of mitapivat in sickle cell disease (SCD). On November 19, 2025, Agios announced topline data that were scientifically interesting and commercially painful at the same time. :contentReference[oaicite:9]{index=9}

In short:

• The trial met its primary endpoint: more patients on mitapivat achieved a meaningful haemoglobin response than on placebo.
• Key lab measures of haemolysis improved versus placebo.
• But the study did not show a statistically significant reduction in annualised pain crises, and there was no clear benefit on fatigue in the overall population. :contentReference[oaicite:10]{index=10}

The market reaction was brutal: AGIO lost roughly half its value in one session as investors had been hoping for a clean, “practice-changing” win on crises – the symptom that dominates SCD patients’ lives. :contentReference[oaicite:11]{index=11}

Despite that, Agios has not walked away from SCD. In its November release and again in the January 2026 strategy update, the company said it intends to:

• hold a pre-sNDA meeting with the FDA in Q1 2026 to discuss the full RISE UP dataset; :contentReference[oaicite:12]{index=12}
• if that discussion is at least partially positive, file an sNDA for mitapivat in SCD during 2026. :contentReference[oaicite:13]{index=13}

Translation: sickle cell is no longer priced as a “done deal”. It is an option – potentially valuable, but sitting on a mixed dataset and a regulatory conversation that will matter more than the stock chart for once.

4. Beyond mitapivat – the rest of the haematology bench

The January 12, 2026 priorities document is useful because it shows that Agios is not planning to become a one-drug company. Alongside mitapivat, the company highlights three additional programmes as part of its “rare-disease haematology” spine. :contentReference[oaicite:14]{index=14}

Tebapivat – second PK activator

Tebapivat is another activator of red-cell metabolism, positioned in:

• Low-risk MDS (LR-MDS) – a Phase 2b trial has completed enrolment, with topline data expected in 1H 2026.
• Sickle cell disease – a Phase 2 study is running, with topline expected in 2H 2026.

If RISE UP with mitapivat leaves SCD in a grey zone, tebapivat becomes a kind of “second shot on goal” in both SCD and MDS, where transfusion burden and anaemia remain major problems.

AG-236 – Polycythaemia vera (PV)

AG-236 targets TMPRSS6 and iron metabolism in polycythaemia vera, aiming to reduce the need for phlebotomies and improve long-term control of red-cell mass. Early clinical data are expected in the first half of 2026, according to the company’s guidance. :contentReference[oaicite:15]{index=15}

AG-181 – Phenylketonuria (PKU)

Finally, AG-181 takes the metabolic know-how into PKU, a rare inherited disorder of phenylalanine metabolism. Agios is running an early proof-of-mechanism study in patients, with data targeted for the second half of 2026. :contentReference[oaicite:16]{index=16}